Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study of CD388

Next Previous
Trial Profile

A phase 3 study of CD388

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CD 388 (Primary)
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 23 Jun 2025 According to a Cidara Therapeutics media release, Cidara has submitted an end of Phase 2 meeting request to the FDA to review the Phase 2b results and further discuss the Phase 3 trial design and start time.
  • 15 May 2025 According to a Cidara Therapeutics media release, company will host a virtual research and development (R&D) day on Thursday, May 22, 2025, from 10:00 to 11:30 AM ET, discuss design of this study.
  • 08 May 2025 According to Cidara Therapeutics media release, dose optimization models for its planned Phase 3 development program was presented at the 38th International Conference on Antiviral Research (ICAR) in March 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top